JP2003506024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506024A5 JP2003506024A5 JP2001513966A JP2001513966A JP2003506024A5 JP 2003506024 A5 JP2003506024 A5 JP 2003506024A5 JP 2001513966 A JP2001513966 A JP 2001513966A JP 2001513966 A JP2001513966 A JP 2001513966A JP 2003506024 A5 JP2003506024 A5 JP 2003506024A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- hgf
- acid ligand
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 239000003446 ligand Substances 0.000 description 20
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 17
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 16
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- JCAQMQLAHNGVPY-UUOKFMHZSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(2,2,4-trioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-7-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical class O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 JCAQMQLAHNGVPY-UUOKFMHZSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53642890A | 1990-06-11 | 1990-06-11 | |
| US09/364,539 US6344321B1 (en) | 1990-06-11 | 1999-07-29 | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| US09/364,543 US6331394B1 (en) | 1991-06-10 | 1999-07-29 | Nucleic acid ligands to integrins |
| US09/364,539 | 1999-07-29 | ||
| US09/364,543 | 1999-07-29 | ||
| PCT/US2000/020139 WO2001009159A1 (en) | 1990-06-11 | 2000-07-24 | Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003506024A JP2003506024A (ja) | 2003-02-18 |
| JP2003506024A5 true JP2003506024A5 (https=) | 2007-09-13 |
Family
ID=48986297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513966A Pending JP2003506024A (ja) | 1990-06-11 | 2000-07-24 | 肝細胞増殖因子／細胞分散因子（ＨＧＦ）又はその受容体ｃ−ｍｅｔ、及びインテグリン類に対する核酸リガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6344321B1 (https=) |
| EP (1) | EP1203007B1 (https=) |
| JP (1) | JP2003506024A (https=) |
| CA (1) | CA2381004A1 (https=) |
| WO (1) | WO2001009159A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166741A1 (en) * | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| US7312325B2 (en) * | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
| US20030118585A1 (en) | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
| US7300922B2 (en) | 2001-05-25 | 2007-11-27 | Duke University | Modulators of pharmacological agents |
| ES2386775T3 (es) | 2001-07-23 | 2012-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| US7435542B2 (en) * | 2002-06-24 | 2008-10-14 | Cornell Research Foundation, Inc. | Exhaustive selection of RNA aptamers against complex targets |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US7670631B2 (en) * | 2003-03-12 | 2010-03-02 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists |
| EP2924119A1 (en) * | 2003-04-21 | 2015-09-30 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| MXPA05013181A (es) * | 2003-06-06 | 2006-06-23 | Genentech Inc | Metodos y composiciones para modular hgf/met. |
| US20050123932A1 (en) * | 2003-12-09 | 2005-06-09 | Mekbib Astatke | Nucleic acid-chelating agent conjugates |
| US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| AU2005220910A1 (en) * | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| WO2005110489A2 (en) * | 2004-04-13 | 2005-11-24 | (Osi) Eyetech, Inc. | Nucleic acid aptamers conjugated to high molecular weight steric groups |
| US7989613B2 (en) * | 2004-10-19 | 2011-08-02 | Texas Tech University | Inhibition of metallo-β-lactamase by RNA |
| CN101258241A (zh) * | 2005-07-05 | 2008-09-03 | 力博美科股份有限公司 | 与免疫球蛋白g结合的核酸及其利用方法 |
| US8637656B2 (en) * | 2005-07-05 | 2014-01-28 | Ribomic Inc. | Nucleic acid capable of binding to immunoglobulin G and use thereof |
| WO2007084886A2 (en) * | 2006-01-17 | 2007-07-26 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| JP4698559B2 (ja) * | 2006-11-24 | 2011-06-08 | Ｎｅｃソフト株式会社 | ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子 |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| CN104402998A (zh) | 2008-07-08 | 2015-03-11 | 昂考梅德药品有限公司 | 分离的抗体 |
| BRPI1011269A2 (pt) * | 2009-05-05 | 2016-09-27 | Altermune Technologies Llc | imunidade quimicamente programável |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2011099576A1 (ja) | 2010-02-12 | 2011-08-18 | 国立大学法人 東京大学 | Ｆｇｆ２に対するアプタマー及びその使用 |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| JPWO2011125458A1 (ja) | 2010-04-02 | 2013-07-08 | 富士レビオ株式会社 | 抗癌剤の効果の診断用マーカー |
| WO2012014890A1 (ja) * | 2010-07-26 | 2012-02-02 | Ｎｅｃソフト株式会社 | ｃ－Ｍｅｔ結合核酸分子およびその用途 |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| AU2011341018A1 (en) * | 2010-12-10 | 2013-07-25 | Merck Patent Gmbh | Aptamer labeled with F-19 nucleus for targeted molecular imaging by MRI |
| US20140301989A1 (en) * | 2011-06-17 | 2014-10-09 | Brian Johnstone | Methods for increasing the potency and efficacy of stem cells |
| GB201114662D0 (en) | 2011-08-24 | 2011-10-12 | Altermune Technologies Llc | Chemically programmable immunity |
| TWI649095B (zh) * | 2012-02-10 | 2019-02-01 | 捷百克股份有限公司 | 以非人類幹細胞之培養上清液為起始材料之化妝品或皮膚再生促進劑、及蛋白質之離子導入法 |
| US9863958B2 (en) * | 2012-04-18 | 2018-01-09 | Lemin Wang | Use of integrin beta subunits in the diagnosis of venous thromboembolism |
| CN104388422B (zh) * | 2014-10-24 | 2017-08-25 | 集美大学 | 寡核苷酸序列及其制备方法与应用 |
| WO2019033051A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR) |
| EP3924467A1 (en) | 2019-02-15 | 2021-12-22 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
| CN114853869B (zh) * | 2019-12-10 | 2023-12-26 | 湖南赛奥维生物技术有限公司 | 一种碱性成纤维细胞生长因子替代物及其组合物和应用 |
| EP4232567A1 (en) | 2020-10-26 | 2023-08-30 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| WO2022216524A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
| MX2023011927A (es) | 2021-04-07 | 2023-10-23 | Century Therapeutics Inc | Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas. |
| US20220333074A1 (en) | 2021-04-07 | 2022-10-20 | Century Therapeutics, Inc. | Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells |
| AU2022299551A1 (en) | 2021-06-23 | 2024-01-18 | Editas Medicine, Inc. | Engineered cells for therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5837834A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
| US5731424A (en) * | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| EP0786469B1 (en) * | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| US5683867A (en) * | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5874218A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| US5472841A (en) * | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
| CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
| AU651452B2 (en) * | 1991-05-10 | 1994-07-21 | Pharmacia & Upjohn S.P.A. | Truncated forms of the hepatocyte growth factor receptor |
| AU732820B2 (en) * | 1995-06-02 | 2001-05-03 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| DE69334159D1 (de) * | 1992-09-18 | 2007-09-13 | Us Gov Health & Human Serv | Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen |
| CA2169536A1 (en) * | 1993-09-08 | 1995-03-16 | Gilead Sciences, Inc. | Nucleic acid ligands and improved methods for producing the same |
-
1999
- 1999-07-29 US US09/364,539 patent/US6344321B1/en not_active Expired - Fee Related
-
2000
- 2000-07-24 WO PCT/US2000/020139 patent/WO2001009159A1/en not_active Ceased
- 2000-07-24 EP EP00948923A patent/EP1203007B1/en not_active Expired - Lifetime
- 2000-07-24 CA CA002381004A patent/CA2381004A1/en not_active Abandoned
- 2000-07-24 JP JP2001513966A patent/JP2003506024A/ja active Pending
-
2006
- 2006-08-22 US US11/508,024 patent/US20070010473A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506024A5 (https=) | ||
| JP2004511201A5 (https=) | ||
| DE3049831C2 (de) | Vektoren enthaltend eine f}r das Oberfl{chenantigen des Hepatites B-Virus kodierende Nucleotidsequenz, Verwendung dieser Vektoren zur Herstellung von Peptiden, Impfstoffe enhaltend dabei erhaltende Peptide als Antigen | |
| JP2002535015A5 (https=) | ||
| JP2002542798A5 (https=) | ||
| WO2005021707A3 (en) | Severe acute respiratory syndrome dna vaccine compositions and methods of use | |
| JP2002541233A5 (https=) | ||
| Ulrich et al. | Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury | |
| JP2011530599A5 (https=) | ||
| JP2002527052A5 (https=) | ||
| DE59913833D1 (de) | Strukturprotein von aav, seine herstellung und verwendung | |
| WO2005055948A3 (en) | Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders | |
| LT3449934T (lt) | Ii tipo glikogeno kaupimo ligos gydymas | |
| JP2003505111A5 (https=) | ||
| JPWO2023015309A5 (https=) | ||
| Jouet et al. | Exon 2 of the gene for neural cell adhesion molecule Ll is alternatively spliced in B cells | |
| ATE238321T1 (de) | Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung | |
| JP2004527469A5 (https=) | ||
| Zhang et al. | Skin tumorigenesis and Ki‐ras and Ha‐ras mutations in tumors from adult mice exposed in utero to 3′‐azido‐2′, 3′‐dideoxythymidine | |
| CN108210510A (zh) | 一种小干扰核酸药物组合物及其用途 | |
| Gupta et al. | Single‐dose pharmacokinetics and tolerability of pegylated interferon‐α2b in young and elderly healthy subjects | |
| JP2004201692A5 (https=) | ||
| ATE325874T1 (de) | Cd154 varianten und deren verwendung | |
| McMahon et al. | Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels | |
| WO2001051489A3 (en) | Methods for lowering uric acid levels |